Please assess the completion status of the following clinical trial:

Trial Title: Neuropsychological Factors Associated With Vulnerability to Suicidal Behavior in Depressed Elderly Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for patients:~* The patient or his/her representative must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* Patients with a diagnosis of current, moderate to severe, major depressive episode according to the DSM diagnostic criteria 5. This episode can be considered as part of a major depressive disorder or bipolar disorder.~* Patients with or without a personal history of suicide attempts. A suicide attempt is defined as any act performed with some intent to die (Mann 1998). Suicidal threats, aborted or interrupted gestures as well as self-mutilating acts without suicidal intent will not be considered as suicidal acts.~* Patients hospitalized (or followed as outpatients) in the Nîmes University Hospital psychiatry department or the Sophoras clinic in Nimes~Inclusion criteria for healthy subjects:~* The subject or his/her representative must have given his/her informed and signed consent~* The subject must be insured or beneficiary of a health insurance plan~* Non-depressed subject without personal history of lifetime mood disorder or severe mental illness, or substance or alcohol abuse during the past 12 months~Exclusion criteria for patients:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection~* The patient (or his/her legal representative) refuses to sign the consent~* It is impossible to correctly inform the patient or his/her legal representative~* The patient has a known MMSE score \<24 (elimination of probable dementia pathology)~* Known central neurological disease including degenerative disease, severe head trauma and severe cerebral vascular disease~* Known schizophrenia and other psychotic disorders~* Alcohol or substance abuse in the last 12 months~* Electroconvulsive therapy in the 12 months preceding the study because of the risk of mnesic side effects~* Inability to perform neuropsychological tests because of a language problem, poor understanding, a major tremor, inability to sit still, a major sight problem that can not be corrected, or other severe cognitive impairment~* The subject presents an acute somatic decompensation incompatible with the completion of this study~* The patient has current confusion~Exclusion criteria for healthy subjects:~* The subject is participating in another study~* The subject is in an exclusion period determined by a previous study~* The subject is under judicial protection~* The subject (or his/her legal representative) refuses to sign the consent~* It is impossible to correctly inform the subject or his/her legal representative~* The subject has a known MMSE score \<24 (elimination of probable dementia pathology)~* Known central neurological disease including degenerative disease, severe head trauma and severe cerebral vascular disease~* Known schizophrenia and other psychotic disorders~* Alcohol or substance abuse in the last 12 months~* Electroconvulsive therapy in the 12 months preceding the study because of the risk of mnesic side effects~* Inability to perform neuropsychological tests because of a language problem, poor understanding, a major tremor, inability to sit still, a major sight problem that can not be corrected, or other severe cognitive impairment~* The subject has a mood disorder~* The subject presents an acute somatic decompensation incompatible with the completion of this study~* Thesubject has current confusion~Pharmacological treatment is not a criterion for exclusion in itself but it will be left to the judgment of the evaluator to choose to include a subject or not (or to postpone inclusion) depending on the drug (eg. after weaning daytime sedative treatment and benzodiazepines).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Major depressive episode (Type: None): This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
- Healthy subjects (Type: None): Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.

Based on this trial design, predict the completion outcome and termination type (if applicable).